160 related articles for article (PubMed ID: 35477518)
1. Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE; Vollenhoven RV; Dörner T; Werth VP; Merrill JT; Furie R; Petronijevic M; Velasco Zamora B; Majdan M; Irazoque-Palazuelos F; Terbrueggen R; Delev N; Weiswasser M; Korish S; Stern M; Hersey S; Ye Y; Gaudy A; Liu Z; Gagnon R; Tang S; Schafer PH
Ann Rheum Dis; 2022 Apr; 81(8):1136-42. PubMed ID: 35477518
[TBL] [Abstract][Full Text] [Related]
2. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
[TBL] [Abstract][Full Text] [Related]
3. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
Furie RA; Hough DR; Gaudy A; Ye Y; Korish S; Delev N; Weiswasser M; Zhan X; Schafer PH; Werth VP
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35169036
[TBL] [Abstract][Full Text] [Related]
4. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.
Rivellese F; Manou-Stathopoulou S; Mauro D; Goldmann K; Pyne D; Rajakariar R; Gordon P; Schafer P; Bombardieri M; Pitzalis C; Lewis MJ
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33727237
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT; Werth VP; Furie R; van Vollenhoven R; Dörner T; Petronijevic M; Velasco J; Majdan M; Irazoque-Palazuelos F; Weiswasser M; Korish S; Ye Y; Gaudy A; Schafer PH; Liu Z; Agafonova N; Delev N
N Engl J Med; 2022 Mar; 386(11):1034-1045. PubMed ID: 35294813
[TBL] [Abstract][Full Text] [Related]
6. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y; Gaudy A; Schafer P; Thomas M; Weiss D; Chen N; Liu L; Xue Y; Carayannopoulos L; Palmisano M
Clin Pharmacol Drug Dev; 2021 May; 10(5):471-485. PubMed ID: 32969202
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
[TBL] [Abstract][Full Text] [Related]
9. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
12. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.
Lyu MA; Tang X; Khoury JD; Raso MG; Huang M; Zeng K; Nishimoto M; Ma H; Sadeghi T; Flowers CR; Parmar S
Front Immunol; 2023; 14():1217121. PubMed ID: 37736101
[TBL] [Abstract][Full Text] [Related]
15. A potential association between IL-3 and type I and III interferons in systemic lupus erythematosus.
Oon S; Monaghan K; Ng M; Hoi A; Morand E; Vairo G; Maraskovsky E; Nash AD; Wicks IP; Wilson NJ
Clin Transl Immunology; 2019; 8(12):e01097. PubMed ID: 31890206
[TBL] [Abstract][Full Text] [Related]
16. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
[TBL] [Abstract][Full Text] [Related]
17. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus.
Dörner T; Tanaka Y; Dow ER; Koch AE; Silk M; Ross Terres JA; Sims JT; Sun Z; de la Torre I; Petri M
Ann Rheum Dis; 2022 Aug; 81(9):1267-1272. PubMed ID: 35609978
[TBL] [Abstract][Full Text] [Related]
19. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study.
Houssiau FA; Thanou A; Mazur M; Ramiterre E; Gomez Mora DA; Misterska-Skora M; Perich-Campos RA; Smakotina SA; Cerpa Cruz S; Louzir B; Croughs T; Tee ML
Ann Rheum Dis; 2020 Mar; 79(3):347-355. PubMed ID: 31871140
[TBL] [Abstract][Full Text] [Related]
20. Systemic lupus erythematosus.
Tanaka Y
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101814. PubMed ID: 36702700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
